Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine: A Phase 1 / 2 Study in Patients with Myelodysplastic Syndrome (ASPEN-02)

▪ Background: Evorpacept is a high affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region designed to enhance the activity of other anti-neoplastic therapies, such as azacitidine (AZA), with minimal additional toxicity. Here, we present results from the phase 1 part of...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2021-11, Vol.138 (Supplement 1), p.2601-2601
Hauptverfasser:	Garcia-Manero, Guillermo, Erba, Harry P., Sanikommu, Srinivasa R., Altman, Jessica K., Sayar, Hamid, Scott, Bart L., Fong, Abraham P., Guan, Shanhong, Jin, Feng, Forgie, Alison J., Pons, Jaume, Randolph, Sophia S., Byrne, Michael T.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!